Kymera Investor Presentation Deck

As of May 1, 2023, data cutoff (ICML): PK and PD profiles in DL1-3 consistent with preclinical data ● ● ● KT-333: Desired Translation of PK, PD and Safety ● Proof-of-mechanism for KT-333 demonstrated with up to 88% mean max degradation of STAT3 in peripheral blood mononuclear cells DL-3 profile is nearing 90% target degradation that led to robust antitumor activity in STAT3-driven preclinical tumor models Most common AEs were Grade 1 and 2 and included fatigue and gastrointestinal symptoms; no DLTs observed or drug related SAEs Initial antitumor activity disclosed in ASH abstract Additional data expected at ASH: Dec. 10, 2023 KYMERA ©2023 KYMERA THERAPEUTICS, INC. First-in-Class Opportunity to Address STAT3-Driven Pathology Across Diverse Indications First heterobifunctional degrader against an undrugged target in the clinic Clinical development strategy includes monotherapy direct registrational path in STAT3 dependent T cell malignancies Opportunity for expansion into solid tumors in combination with immune checkpoint inhibitors to be informed by preclinical data and planned analysis of TME remodeling in solid tumor biopsies from ongoing trial PAGE 30

View entire presentation